A study to evaluate efficacy and safety of ASP8232 as add-on therapy to the standard of care in patients with Type 2 Diabetes and Chronic Kidney Disease.

Registry ID

EUCTR2014-002349-23

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Astellas Pharma Europe BV (APEB)

Start date

2014-12-12

Completion date

2017-03-15

Last update

2026-08-16

Conditions

• Diabetic nephropathy

Summary

To evaluate the efficacy of ASP8232 in reducing Urinary Albumin to Creatinine Ratio (UACR) in subjects with Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) at 12 weeks compared to placebo.

Locations

• , , Belgium
• , , Germany
• , , Spain
• , , Italy
• , , Hungary
• , , Poland
• , , Netherlands
• , , Denmark
• , , UK
• , , Czechia

View on source registry